ZD6126

ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol, related to colchicine.[1] It has shown promising results on tumors in mice.[2]

ZD6126
Clinical data
Other namesANG 453; AZD 6126; N-Acetylcolchicinol dihydrogenphosphate
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H24NO8P
Molar mass437.385 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

A phase I clinical trial identified gastrointestinal and cardiac effects as limiting dosing.[3] Two phase II clinical trials were suspended investigating ZD6126 in metastatic renal cell carcinoma and metastatic colorectal cancer.[4]

ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent (VDA). However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.[5]

References

  1. "ZD6126". NCI Drug Dictionary. U.S. National Cancer Institute.
  2. Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S (July 2002). "Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice". Cancer Research. 62 (13): 3711–5. PMID 12097279.
  3. LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, et al. (April 2008). "Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors". Investigational New Drugs. 26 (2): 159–67. doi:10.1007/s10637-008-9112-9. PMID 18219445. S2CID 40419869.
  4. "ZD6126". ClinicalTrialsGov. U.S. National Library of Medicine.
  5. Lippert JW (January 2007). "Vascular disrupting agents". Bioorganic & Medicinal Chemistry. 15 (2): 605–15. doi:10.1016/j.bmc.2006.10.020. PMID 17070061.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.